TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR TABLET

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Fáanlegur frá:

TEVA CANADA LIMITED

ATC númer:

J05AR06

INN (Alþjóðlegt nafn):

EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ

Skammtar:

600MG; 200MG; 300MG

Lyfjaform:

TABLET

Samsetning:

EFAVIRENZ 600MG; EMTRICITABINE 200MG; TENOFOVIR DISOPROXIL FUMARATE 300MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

30

Gerð lyfseðils:

Prescription

Lækningarsvæði:

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Vörulýsing:

Active ingredient group (AIG) number: 0352327001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2017-07-26

Vara einkenni

PRODUCT MONOGRAPH
PR
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Efavirenz, Emtricitabine and Tenofovir Tablets
Teva Standard
600 mg/200 mg/300 mg
(efavirenz/emtricitabine/tenofovir disoproxil fumarate)
Antiretroviral Agent
Teva Canada Limited
Date of Revision:
30 Novopharm Court
June 1, 2020
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Control No.: 238915
_TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR Product Monograph _
_ _
_ _
_ _
_ 2 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................................3
INDICATIONS AND CLINICAL USE
.......................................................................................3
CONTRAINDICATIONS
............................................................................................................3
WARNINGS AND PRECAUTIONS
...........................................................................................4
ADVERSE REACTIONS
...........................................................................................................15
DRUG INTERACTIONS
...........................................................................................................23
DOSAGE AND ADMINISTRATION
.......................................................................................39
OVERDOSAGE
.........................................................................................................................39
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................40
STORAGE AND STABILITY
...................................................................................................44
SPECIAL HANDLING INSTRUCTIONS
................................................................................44
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................44
PART II: SCIENTIFIC INFORMATION
..................................